<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Adv Pharm Technol Res</journal-id><journal-id journal-id-type="iso-abbrev">J Adv Pharm Technol Res</journal-id><journal-id journal-id-type="publisher-id">JAPTR</journal-id><journal-title-group><journal-title>Journal of Advanced Pharmaceutical Technology &#x00026; Research</journal-title></journal-title-group><issn pub-type="ppub">2231-4040</issn><issn pub-type="epub">0976-2094</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7832196</article-id><article-id pub-id-type="publisher-id">JAPTR-12-79</article-id><article-id pub-id-type="doi">10.4103/japtr.JAPTR_85_20</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Synergistic effect of ampicillin and dihydrobenzofuran neolignans (myticaganal C) identified from the seeds of <italic>Myristica fragrans</italic> Houtt. against <italic>Escherichia coli</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Keawchai</surname><given-names>Kanokrat</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chumkaew</surname><given-names>Parinuch</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Permpoonpattana</surname><given-names>Patima</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Srisawat</surname><given-names>Theera</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Agricultural Science and Technology, Faculty of Science and Industrial Technology, Prince of Songkla University, Surat Thani Campus, Surat Thani, Thailand</aff><aff id="aff2"><label>2</label>Department of Agricultural Science, Faculty of Innovative Agriculture and Fisheries, Prince of Songkla University, Surat Thani Campus, Surat Thani, Thailand</aff><author-notes><corresp id="cor1"><bold>Address for correspondence: </bold> Dr. Theera Srisawat, Faculty of Science and Industrial Technology, Prince of Songkla University, Surat Thani Campus, 31 Moo 6, Tambol Makham Tia, Muang Surat Thani District, Surat Thani 84000; Faculty of Innovative Agriculture and Fisheries, Prince of Songkla University, Surat Thani Campus, 31 Moo 6, Tambol Makham Tia, Muang Surat Thani District, Surat Thani 84000, Thailand. E-mail: <email xlink:href="theera.s@psu.ac.th">theera.s@psu.ac.th</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2021</year></pub-date><pub-date pub-type="epub"><day>09</day><month>1</month><year>2021</year></pub-date><volume>12</volume><issue>1</issue><fpage>79</fpage><lpage>83</lpage><history><date date-type="received"><day>23</day><month>6</month><year>2020</year></date><date date-type="rev-recd"><day>19</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>08</day><month>9</month><year>2020</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2021 Journal of Advanced Pharmaceutical Technology &#x00026; Research</copyright-statement><copyright-year>2021</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0"><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><p>The present study was designed to enhance the antibacterial activity of ampicillin against <italic>Escherichia coli</italic> by combining it with myticaganal C. Antibacterial activity of ampicillin combined with myticaganal C against <italic>E. coli</italic> was assessed by agar well diffusion. Minimum inhibitory concentrations (MICs) and synergy by checkerboard assay of ampicillin and myticaganal C were assessed by resazurin-based 96-well microdilution. Bacterial responses were assessed by flow cytometry. Ampicillin in combination with myticaganal C showed better zone of inhibition (31.67 &#x000b1; 0.58 mm) than myticaganal C or ampicillin alone. MIC of ampicillin was found to be 12.5 &#x003bc;g/mL, but myticaganal C was ineffective against <italic>E. coli</italic>. Myticaganal C (8000 &#x003bc;g/mL) with ampicillin (0.0975 &#x003bc;g/mL) exhibited strong synergy, so the need for ampicillin was reduced 128-fold. Combination inhibited <italic>E. coli</italic> by acting on cell membrane and by granularity disruptions. These findings indicate that myticaganal C enhances the potential of ampicillin against <italic>E. coli</italic>, thus providing an effective alternative to deal with the problem of bacterial resistance.</p></abstract><kwd-group><title>Key words:</title><kwd>Ampicillin</kwd><kwd>checkerboard assay</kwd><kwd>flow cytometry</kwd><kwd>myticaganal C</kwd><kwd>synergistic effect</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Resistant bacterial strains are known to evolve into antibiotic-resistant forms, with modified hereditary materials.[<xref rid="ref1" ref-type="bibr">1</xref>] This is becoming the main cause of failures in the treatment of diseases. Developing novel approaches is to complement known antibiotics with secondary metabolites. Several studies have reported that secondary metabolites decreased the amount of antibiotics needed while increasing the antibacterial activity of the treatment.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>]</p><p>Plant secondary metabolites could enhance antibacterial activity when combined with antibiotics.[<xref rid="ref4" ref-type="bibr">4</xref>] Some secondary metabolites, namely dihydrobenzofuran-type neolignans, have been associated with various activities.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] These compounds have been reported as antibacterial agents against pathogens.[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>] <italic>Myristica fragrans</italic> Houtt. is an important plant source of neolignans used for preventing cancer and leishmaniasis.[<xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref>] The activity-guided fractionation of crude extract from <italic>M. fragrans</italic> seeds has led to the isolation of myticaganal C.[<xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>] The effects of this compound on pathogenic bacteria have not been reported. There is no information regarding synergy of the compound extracted from <italic>M. fragrans</italic> seeds, with antibiotics against pathogenic bacteria. Gram-negative <italic>E. coli</italic> bacteria are most commonly commensal and can also be pathogenic in humans.[<xref rid="ref15" ref-type="bibr">15</xref>] Resistant <italic>E. coli</italic> strains to antibiotics are risky as they are the most common Gram-negative bacteria infecting humans, and there are strains with extended-spectrum &#x003b2;-lactamases.[<xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref>] This study was aimed at determining the antibacterial activities of ampicillin and myticaganal C alone and as combinations against <italic>E. coli</italic>.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><sec id="sec2-1"><title>Chemicals and bacterial strain</title><p>Myticaganal C [<xref ref-type="fig" rid="F1">Figure 1</xref>] was purified from ethyl acetate&#x02013;hexane (1:4) extract of <italic>M. fragrans</italic> seeds using the method previously described by Chumkaew and Srisawat.[<xref rid="ref14" ref-type="bibr">14</xref>] Ampicillin was obtained from HiMedia (HiMedia Laboratories Pvt. Ltd., Mumbai, India). The tested organism was <italic>E. coli</italic> ATCC 25922.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Chemical structure of myticaganal C from the seeds of <italic>Myristica fragrans</italic>[<xref rid="ref14" ref-type="bibr">14</xref>]</p></caption><graphic xlink:href="JAPTR-12-79-g001"/></fig></sec><sec id="sec2-2"><title>Agar well diffusion</title><p>Briefly, the antibacterial activity was tested on Mueller&#x02013;Hinton agar by agar well diffusion method. After the culture of 10<sup>8</sup> CFU/mL concentration of <italic>E. coli</italic> suspension was swabbed on the plates, wells (6 mm diameter) were punched in each plate using a cork borer. Then, each well was filled with 50 &#x003bc;L of myticaganal C (125&#x02013;4000 &#x003bc;g/well), or ampicillin (3.125 and 50 &#x003bc;g/well), or mixture of myticaganal C (125&#x02013;4000 &#x003bc;g/well) with ampicillin (3.125 and 50 &#x003bc;g/well). Inoculated plates were incubated at 37&#x000b0;C for 24 h. The antibacterial activity is expressed as mean of the growth inhibition zone in millimeters.</p></sec><sec id="sec2-3"><title>Determination of minimum inhibitory concentration</title><p>280 &#x003bc;L of mixed solution of Mueller&#x02013;Hinton Broth (MHB) and two-fold myticaganal C (8000 &#x003bc;g/mL) or ampicillin (200 &#x003bc;g/mL) was filled in the first well of 96-well plate. Wells 2&#x02013;8 had 140 &#x003bc;L MHB. To prepare myticaganal C concentrations of 62.5&#x02013;8000 &#x003bc;g/mL or ampicillin concentrations of 1.56&#x02013;200 &#x003bc;g/mL, 140 &#x003bc;L aliquot from the first well was pipetted and filled into the next well to make a two-fold serial microdilution in the 96-well plate. 50 &#x003bc;L of <italic>E. coli</italic> suspension was added into each well. The 96-well plate was then incubated at 37&#x000b0;C for 24 h. Then, 0.015% resazurin (10 &#x003bc;L) was added into each well, and it was further incubated before measuring for a color change. The minimum inhibitory concentration (MIC) was defined as the lowest concentration of the tested compound that prevented oxidation of the blue dye to a pink resorufin product.[<xref rid="ref18" ref-type="bibr">18</xref>]</p></sec><sec id="sec2-4"><title>Checkerboard 96-well plate assay</title><p>Two-fold serial dilutions of myticaganal C and ampicillin were performed, until reducing concentration of each substance 128-fold. Columns 1&#x02013;8 and rows A&#x02013;H were used to test mixtures of myticaganal C (62.5&#x02013;8000 &#x003bc;g/mL) and ampicillin (0.0975&#x02013;12.5 &#x003bc;g/mL), respectively. Columns 9A&#x02013;9H were used for ampicillin alone (1.56&#x02013;200 &#x003bc;g/mL). Columns 10A&#x02013;10H were used to test myticaganal C alone (62.5&#x02013;8000 &#x003bc;g/mL). 50 &#x003bc;L of bacterial solution was added into each well. Then, the final volume was 190 &#x003bc;L. The plates were incubated for 24 h at 37&#x000b0;C before adding 0.015% resazurin. The plate was then determined for color changes, as described above.</p><p>The synergy between ampicillin and myticaganal C was estimated as a fractional inhibitory concentration index following the method described by Mohammadi <italic>et al</italic>.[<xref rid="ref19" ref-type="bibr">19</xref>]</p></sec><sec id="sec2-5"><title>Flow cytometric determination of cell membrane permeability and granular integrity of <italic>Escherichia coli</italic></title><p>The final concentrations that corresponded to 0.5 MIC (0.049 &#x003bc;g/mL of ampicillin: 8000 &#x003bc;g/mL of myticaganal C), MIC (0.098 &#x003bc;g/mL of ampicillin: 8000 &#x003bc;g/mL of myticaganal C), and 2 MIC (0.196 &#x003bc;g/mL of ampicillin: 8000 &#x003bc;g/mL of myticaganal C) were added to wells containing 5 &#x000d7; 10<sup>6</sup> CFU/mL and incubated at 37&#x000b0;C for 0&#x02013;24 h. After incubation, the cells were washed and re-suspended in 950 &#x003bc;L of phosphate-buffered saline. Samples were then incubated with 50 &#x003bc;g/mL propidium iodide in the dark for 15 min. The samples were analyzed on BD FACSCalibur flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA). The populations of each sample were analyzed on density plot diagrams generated by WinMDI version 2.9 software (Scripps Institute, La Jolla, CA, USA).</p></sec><sec id="sec2-6"><title>Data analysis</title><p>One-way ANOVA was used for antibacterial zones of inhibition by myticaganal C in combination with ampicillin. A <italic>P</italic> &#x0003c; 0.05 was considered statistically significant. Results are reported as mean &#x000b1; standard deviation. All calculations were done using SPSS version 11.0 software (IBM Corp., Armonk, NY, USA).</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><sec id="sec2-7"><title>Antibacterial activity</title><p>The antibacterial activity of ampicillin (3.125 and 50 &#x003bc;g/well) and myticaganal C (125&#x02013;4000 &#x003bc;g/well) singly and synergy of these substances against <italic>E. coli</italic> ATCC 25922 were evaluated by measuring the zone of inhibition of bacterial growth around the hole. The results showed that ampicillin had significant activity against <italic>E. coli</italic>, with 27.33 &#x000b1; 0.58 mm inhibition zone. However, the tested organisms did not show any zone of inhibition with any tested concentration of myticaganal C singly. Interestingly, the growth of tested organisms was significantly inhibited synergistically with high inhibition by 50 &#x003bc;g/well of ampicillin combined with any tested concentration of myticaganal C, giving 31.67 &#x000b1; 0.58 mm inhibition zone [<xref rid="T1" ref-type="table">Table 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Antibacterial activity of ampicillin, myticaganal C, and the combination of myticaganal C with ampicillin against <italic>Escherichia coli</italic> ATCC 25922</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Extract concentration (&#x000b5;g/well)</th><th valign="top" align="center" rowspan="1" colspan="1">Zone of inhibition (mm)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Alone</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Ampicillin</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;50</td><td valign="top" align="center" rowspan="1" colspan="1">27.33&#x000b1;0.58<sup>c</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;3.125</td><td valign="top" align="center" rowspan="1" colspan="1">13.33&#x000b1;0.58<sup>e</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Myticaganal C</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;4000</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;2000</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;1000</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;500</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;250</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;125</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Combination</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Ampicillin with Myticaganal C</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;50:4000</td><td valign="top" align="center" rowspan="1" colspan="1">31.67&#x000b1;0.58<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;50:2000</td><td valign="top" align="center" rowspan="1" colspan="1">31.67&#x000b1;0.58<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;50:1000</td><td valign="top" align="center" rowspan="1" colspan="1">31.67&#x000b1;0.58<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;50:500</td><td valign="top" align="center" rowspan="1" colspan="1">31.33&#x000b1;0.58a<sup>b</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;50:250</td><td valign="top" align="center" rowspan="1" colspan="1">30.67&#x000b1;0.58<sup>b</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;50:125</td><td valign="top" align="center" rowspan="1" colspan="1">30.67&#x000b1;0.58<sup>b</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;3.125:4000</td><td valign="top" align="center" rowspan="1" colspan="1">20.67&#x000b1;0.58<sup>d</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;3.125:2000</td><td valign="top" align="center" rowspan="1" colspan="1">20.67&#x000b1;0.58<sup>d</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;3.125:1000</td><td valign="top" align="center" rowspan="1" colspan="1">20.33&#x000b1;0.58<sup>d</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;3.125:500</td><td valign="top" align="center" rowspan="1" colspan="1">20.67&#x000b1;0.58<sup>d</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;3.125:250</td><td valign="top" align="center" rowspan="1" colspan="1">20.33&#x000b1;0.58<sup>d</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;3.125:125</td><td valign="top" align="center" rowspan="1" colspan="1">20.00&#x000b1;0.00<sup>d</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;5% DMSO</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn><p>Values are mean inhibition zone diameter (mm)&#x000b1;SD from three replicates. Statistically significant differences between dose levels are shown by different superscripts, based on DMRT (<italic>P</italic>=0.05). SD: Standard deviation, DMRT: Duncan&#x02019;s multiple range test, DMSO: Dimethyl sulfoxide</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-8"><title>Minimal inhibitory concentration of ampicillin and myticaganal C alone and their combinations</title><p>After 24 h of incubation, unchanged resazurin blue color was observed for the wells with 12.5&#x02013;200 &#x003bc;g/mL of ampicillin, whereas the wells with myticaganal C did not show any inhibition (resazurin changed from blue to pink) [<xref ref-type="fig" rid="F2">Figure 2</xref>]. The wells containing 0.0975 and 0.195 &#x003bc;g/mL of ampicillin combined with 8000 &#x003bc;g/mL myticaganal C had the resazurin blue color. Therefore, the MICs of ampicillin alone and ampicillin and myticaganal C in combination were 12.5 &#x003bc;g/mL and 0.0975 and 8000 &#x003bc;g/mL, respectively. Myticaganal C at 8000 &#x003bc;g/mL reduced the MIC of ampicillin 128-fold from that of ampicillin alone, against <italic>E. coli</italic>.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Synergistic effect of Myticaganal C with ampicillin against <italic>Escherichia coli</italic> tested by the checkerboard assay</p></caption><graphic xlink:href="JAPTR-12-79-g002"/></fig></sec><sec id="sec2-9"><title>Effects of myticaganal C combined with ampicillin on membrane permeability and granular integrity of <italic>Escherichia coli</italic> ATCC 25922</title><p>An investigation of the mortality rates and the response patterns of <italic>E. coli</italic> when treated with 0.5 MIC, MIC, and 2 MIC of ampicillin combined with myticaganal C for 12 h involved the identification of four populations [<xref ref-type="fig" rid="F3">Figure 3</xref>]. The synergy of ampicillin with myticaganal C was observed to be dose dependent, with 12 h of incubation, as the rates of dead cells when treated at 0.5 MIC, MIC, and 2 MIC of the synergistic plant&#x02013;antibiotic mix were 2.4%, 4.7%, and 9.3%, respectively [<xref rid="T2" ref-type="table">Table 2</xref>]. The response pattern of the bacterial cells to ampicillin with myticaganal C inhibited <italic>E. coli</italic> by both cell membrane damage and granularity disruption.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Flow cytometry dot plots for <italic>Escherichia coli</italic> treated with 8000 &#x003bc;g/mL of myticaganal C (a), 12.5 &#x003bc;g/mL of ampicillin (b), 0.0975 &#x003bc;g/mL of ampicillin (c), 0.5 minimum inhibitory concentration (d), minimum inhibitory concentration (e), and 2 minimum inhibitory concentration (f), for 12 h. *The regions divided by the lines were interpreted as: lower left for viable cells, lower right for membrane-damaged cells, upper left for injured cells, and upper right for dead cells</p></caption><graphic xlink:href="JAPTR-12-79-g003"/></fig><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>The combination of myticaganal C with ampicillin at 0.5 minimum inhibitory concentration, minimum inhibitory concentration, and 2 minimum inhibitory concentration (12 h treatment with each) caused responses in bacterial cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="2" colspan="1">Treatment</th><th valign="top" align="center" colspan="5" rowspan="1">Response pattern of <italic>Escherichia coli</italic> ATCC 25922<hr/></th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">Cell viability</th><th valign="top" align="center" rowspan="1" colspan="1">Damaged cell membranes</th><th valign="top" align="center" rowspan="1" colspan="1">Disrupted cell granularity</th><th valign="top" align="center" rowspan="1" colspan="1">Cell death</th><th valign="top" align="center" rowspan="1" colspan="1">Other than viable</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">5% DMSO</td><td valign="top" align="center" rowspan="1" colspan="1">97.7</td><td valign="top" align="center" rowspan="1" colspan="1">0.3</td><td valign="top" align="center" rowspan="1" colspan="1">1.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.8</td><td valign="top" align="center" rowspan="1" colspan="1">2.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Myticaganal C</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;8000 &#x000b5;g/mL</td><td valign="top" align="center" rowspan="1" colspan="1">88.0</td><td valign="top" align="center" rowspan="1" colspan="1">0.6</td><td valign="top" align="center" rowspan="1" colspan="1">5.8</td><td valign="top" align="center" rowspan="1" colspan="1">5.5</td><td valign="top" align="center" rowspan="1" colspan="1">11.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ampicillin (&#x000b5;g/mL)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12.5</td><td valign="top" align="center" rowspan="1" colspan="1">90.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.3</td><td valign="top" align="center" rowspan="1" colspan="1">8.1</td><td valign="top" align="center" rowspan="1" colspan="1">0.8</td><td valign="top" align="center" rowspan="1" colspan="1">9.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;0.0975</td><td valign="top" align="center" rowspan="1" colspan="1">95.8</td><td valign="top" align="center" rowspan="1" colspan="1">1.7</td><td valign="top" align="center" rowspan="1" colspan="1">1.5</td><td valign="top" align="center" rowspan="1" colspan="1">1.0</td><td valign="top" align="center" rowspan="1" colspan="1">4.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Combination treatment</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;0.5 MIC</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;0.049:8000 &#x000b5;g/mL</td><td valign="top" align="center" rowspan="1" colspan="1">95.2</td><td valign="top" align="center" rowspan="1" colspan="1">1.9</td><td valign="top" align="center" rowspan="1" colspan="1">0.5</td><td valign="top" align="center" rowspan="1" colspan="1">2.4</td><td valign="top" align="center" rowspan="1" colspan="1">4.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MIC</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;0.0975:8000 &#x000b5;g/mL</td><td valign="top" align="center" rowspan="1" colspan="1">91.9</td><td valign="top" align="center" rowspan="1" colspan="1">2.6</td><td valign="top" align="center" rowspan="1" colspan="1">0.8</td><td valign="top" align="center" rowspan="1" colspan="1">4.7</td><td valign="top" align="center" rowspan="1" colspan="1">8.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2 MIC</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;0.195:8000 &#x000b5;g/mL</td><td valign="top" align="center" rowspan="1" colspan="1">80.1</td><td valign="top" align="center" rowspan="1" colspan="1">9.7</td><td valign="top" align="center" rowspan="1" colspan="1">0.9</td><td valign="top" align="center" rowspan="1" colspan="1">9.3</td><td valign="top" align="center" rowspan="1" colspan="1">19.9</td></tr></tbody></table><table-wrap-foot><fn><p>MIC: Minimum inhibitory concentration, DMSO: Dimethyl sulfoxide</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Antibiotic-resistant bacterial strains are an emerging threat to the health of people worldwide.[<xref rid="ref20" ref-type="bibr">20</xref>] There is an urgent need to discover novel alternative treatments complementing the use of antibiotics. The synergy of medicinal plant compounds with antibiotics is of interest in this context. In many previous studies, plant compounds combined with antibiotics have delayed the emergence of resistant bacteria.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref21" ref-type="bibr">21</xref>] This study aimed at finding antibacterial synergy between a compound from a medicinal plant and an antibiotic, to inhibit the growth of <italic>E. coli</italic>.</p><p>In experiments, ampicillin combined with myticaganal C showed a good inhibition zone against <italic>E. coli</italic>, better than myticaganal C or ampicillin alone. Dihydrobenzofuran neolignans are secondary metabolites in a plant extract such that they have bioactive activities.[<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref>] On the other hand, antibacterial action of dihydrobenzofuran neolignans against an agent panel of cariogenic bacteria has been reported by Fukui <italic>et al</italic>.[<xref rid="ref7" ref-type="bibr">7</xref>] Ampicillin is a &#x003b2;-lactam antibiotic that inhibits cell wall peptidoglycan synthesis of bacteria.[<xref rid="ref22" ref-type="bibr">22</xref>] Then, the bacterial cell wall becomes mechanically weak and the cell dies.[<xref rid="ref23" ref-type="bibr">23</xref>] After cell wall disruption, lipophilicity of the dihydrobenzofuran neolignans might allow these compounds to diffuse across the cell membrane.[<xref rid="ref7" ref-type="bibr">7</xref>] After passing the cell membrane, the compound could affect bacterial metabolism and organelles causing death to the bacteria. The MIC of ampicillin combined with myticaganal C indicates that myticaganal C reduced the MIC of ampicillin 128-fold to 0.097 &#x003bc;g/mL from the 12.5 &#x003bc;g/mL MIC of ampicillin alone. These results resemble those obtained by Navr&#x000e1;tilov&#x000e1; <italic>et al</italic>.,[<xref rid="ref24" ref-type="bibr">24</xref>] who reported on efficacy of a medicinal plant that can increase the antibacterial activity of antibiotics. Similarly, trihydroxyflavone from <italic>M. fragrans</italic> could increase the activity of tetracycline against Gram-negative bacteria.[<xref rid="ref25" ref-type="bibr">25</xref>]</p><p>The results of flow cytometry indicate that ampicillin combined with myticaganal C inhibited <italic>E. coli</italic> both by acting on cell membrane and by granularity disruptions. This synergy decreased viability and increased mortality of the bacteria in a dose-dependent manner.</p></sec><sec sec-type="conclusions" id="sec1-5"><title>CONCLUSION</title><p>The results of this study indicate improved antibacterial efficacy against <italic>E. coli</italic> ATCC 25922 of ampicillin when supplemented with myticaganal C. The supplementation could reduce 128-fold the effective dose of ampicillin, while the supplement alone had no activity against these bacteria. Further studies are needed to evaluate the <italic>in vivo</italic> effects, as well as possible additional mechanisms underlying the antibacterial activities.</p><sec id="sec2-10"><title>Financial support and sponsorship</title><p>This study was financially supported by grants from the Graduate School, Prince of Songkla University and Prince of Songkla University Surat Thani campus funding. The authors would like to thank Dr. Seppo Karrila for English proofreading.</p></sec><sec id="sec2-11" sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandar</surname><given-names>B</given-names></name><name><surname>Poovitha</surname><given-names>S</given-names></name><name><surname>Ilango</surname><given-names>K</given-names></name><name><surname>MohanKumar</surname><given-names>R</given-names></name><name><surname>Parani</surname><given-names>M</given-names></name></person-group><article-title>Inhibition of New Delhi metallo-&#x003b2;-lactamase 1 (NDM-1) producing <italic>Escherichia coli</italic> IR-6 by selected plant extracts and their synergistic actions with antibiotics</article-title><source>Front Microbiol</source><year>2017</year><volume>8</volume><fpage>1580</fpage><pub-id pub-id-type="pmid">28878746</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>N</given-names></name><name><surname>Ashrafuzzaman</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>H</given-names></name><name><surname>Liza</surname><given-names>LN</given-names></name><name><surname>Zinnah</surname><given-names>MA</given-names></name></person-group><article-title>Antimicrobial activity of some medicinal plants against multi drug resistant human pathogens</article-title><source>Adv Biosci Bioeng</source><year>2013</year><volume>1</volume><fpage>1</fpage><lpage>24</lpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masoumian</surname><given-names>M</given-names></name><name><surname>Zandi</surname><given-names>M</given-names></name></person-group><article-title>Antimicrobial activity of some medicinal plant extracts against multidrug resistant bacteria</article-title><source>Zahedan J Res Med Sci</source><year>2017</year><volume>19</volume><fpage>e10080</fpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semeniuc</surname><given-names>CA</given-names></name><name><surname>Pop</surname><given-names>CR</given-names></name><name><surname>Rotar</surname><given-names>AM</given-names></name></person-group><article-title>Antibacterial activity and interactions of plant essential oil combinations against Gram-positive and Gram-negative bacteria</article-title><source>J Food Drug Anal</source><year>2017</year><volume>25</volume><fpage>403</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">28911683</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teponno</surname><given-names>RB</given-names></name><name><surname>Kusari</surname><given-names>S</given-names></name><name><surname>Spiteller</surname><given-names>M</given-names></name></person-group><article-title>Recent advances in research on lignans and neolignans</article-title><source>Nat Prod Rep</source><year>2016</year><volume>33</volume><fpage>1044</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">27157413</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname><given-names>O</given-names></name><name><surname>Gomes</surname><given-names>L</given-names></name><name><surname>Brito</surname><given-names>LM</given-names></name><name><surname>Alves</surname><given-names>MM</given-names></name><name><surname>Amorim</surname><given-names>LV</given-names></name><name><surname>Sobrinho-J&#x000fa;nior</surname><given-names>EP</given-names></name><etal/></person-group><article-title><italic>In vitro</italic> effects of the neolignan 2,3-dihydrobenzofuran against <italic>Leishmania amazonensis</italic></article-title><source>Basic Clin Pharmacol Toxicol</source><year>2017</year><volume>120</volume><fpage>52</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">27398818</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukui</surname><given-names>MJ</given-names></name><name><surname>Dias</surname><given-names>HJ</given-names></name><name><surname>Severiano</surname><given-names>ME</given-names></name><name><surname>Souza</surname><given-names>GM</given-names></name><name><surname>Oliveira</surname><given-names>PF</given-names></name><name><surname>Ambr&#x000f3;sio</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Antimicrobial and cytotoxic activity of dihydrobenzofuran neolignans</article-title><source>ChemistrySelect</source><year>2018</year><volume>3</volume><fpage>1836</fpage><lpage>9</lpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>ZL</given-names></name><name><surname>He</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Ma</surname><given-names>R</given-names></name><name><surname>Khondkar</surname><given-names>P</given-names></name><name><surname>Kaatz</surname><given-names>GW</given-names></name><etal/></person-group><article-title>Benzocyclohexane oxide derivatives and neolignans from: Piper betle inhibit efflux-related resistance in <italic>Staphylococcus aureus</italic></article-title><source>R Soc Chem Adv</source><year>2016</year><volume>6</volume><fpage>43518</fpage><lpage>25</lpage></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de La Cruz-S&#x000e1;nchez</surname><given-names>NG</given-names></name><name><surname>G&#x000f3;mez-Rivera</surname><given-names>A</given-names></name><name><surname>Alvarez-Fitz</surname><given-names>P</given-names></name><name><surname>Ventura-Zapata</surname><given-names>E</given-names></name><name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>MD</given-names></name><name><surname>Avil&#x000e9;s-Flores</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antibacterial activity of Morinda citrifolia Linneo seeds against methicillin-resistant <italic>Staphylococcus</italic> spp</article-title><source>Microb Pathog</source><year>2019</year><volume>128</volume><fpage>347</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">30682527</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranaware</surname><given-names>AM</given-names></name><name><surname>Banik</surname><given-names>K</given-names></name><name><surname>Deshpande</surname><given-names>V</given-names></name><name><surname>Padmavathi</surname><given-names>G</given-names></name><name><surname>Roy</surname><given-names>NK</given-names></name><name><surname>Sethi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Magnolol: A neolignan from the Magnolia family for the prevention and treatment of cancer</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><fpage>1</fpage><lpage>21</lpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>GD</given-names></name><name><surname>Lu</surname><given-names>LW</given-names></name><name><surname>Song</surname><given-names>XY</given-names></name><name><surname>Lin</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>XB</given-names></name><etal/></person-group><article-title>Neolignans from red raspberry (<italic>Rubus idaeus</italic> L.) exhibit enantioselective neuroprotective effects against H2O2-induced oxidative injury in SH-SY5Y cells</article-title><source>J Agric Food Chem</source><year>2018</year><volume>66</volume><fpage>11390</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">30346163</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaral</surname><given-names>M</given-names></name><name><surname>de Sousa</surname><given-names>FS</given-names></name><name><surname>Silva</surname><given-names>TA</given-names></name><name><surname>Junior</surname><given-names>AJ</given-names></name><name><surname>Taniwaki</surname><given-names>NN</given-names></name><name><surname>Johns</surname><given-names>DM</given-names></name><etal/></person-group><article-title>A semi-synthetic neolignan derivative from dihydrodieugenol B selectively affects the bioenergetic system of <italic>Leishmania infantum</italic> and inhibits cell division</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><fpage>6114</fpage><pub-id pub-id-type="pmid">30992481</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abourashed</surname><given-names>EA</given-names></name><name><surname>El-Alfy</surname><given-names>AT</given-names></name></person-group><article-title>Chemical diversity and pharmacological significance of the secondary metabolites of nutmeg (<italic>Myristica fragrans</italic> Houtt.)</article-title><source>Phytochem Rev</source><year>2016</year><volume>15</volume><fpage>1035</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">28082856</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chumkaew</surname><given-names>P</given-names></name><name><surname>Srisawat</surname><given-names>T</given-names></name></person-group><article-title>New neolignans from the seeds of <italic>Myristica fragrans</italic> and their cytotoxic activities</article-title><source>J Nat Med</source><year>2019</year><volume>73</volume><fpage>273</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">30168038</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amenu</surname><given-names>D</given-names></name></person-group><article-title>Antimicrobial activity of medicinal plant extracts and their synergistic effect on some selected pathogens</article-title><source>Am J Ethnomed</source><year>2014</year><volume>1</volume><fpage>18</fpage><lpage>29</lpage></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fair</surname><given-names>RJ</given-names></name><name><surname>Tor</surname><given-names>Y</given-names></name></person-group><article-title>Antibiotics and bacterial resistance in the 21st century</article-title><source>Perspect Medicin Chem</source><year>2014</year><volume>6</volume><fpage>25</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">25232278</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhillon</surname><given-names>RH</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name></person-group><article-title>ESBLs: A clear and present danger?</article-title><source>Crit Care Res Pract</source><year>2012</year><volume>2012</volume><fpage>625170</fpage><pub-id pub-id-type="pmid">21766013</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elshikh</surname><given-names>M</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Funston</surname><given-names>S</given-names></name><name><surname>Dunlop</surname><given-names>P</given-names></name><name><surname>McGaw</surname><given-names>M</given-names></name><name><surname>Marchant</surname><given-names>R</given-names></name><etal/></person-group><article-title>Resazurin-based 96-well plate microdilution method for the determination of minimum inhibitory concentration of biosurfactants</article-title><source>Biotechnol Lett</source><year>2016</year><volume>38</volume><fpage>1015</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">26969604</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Khayat</surname><given-names>H</given-names></name><name><surname>Sayehmiri</surname><given-names>K</given-names></name><name><surname>Soroush</surname><given-names>S</given-names></name><name><surname>Sayehmiri</surname><given-names>F</given-names></name><name><surname>Delfani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Synergistic effect of colistin and rifampin against multidrug resistant <italic>Acinetobacter baumannii</italic>: A systematic review and meta-analysis</article-title><source>Open Microbiol J</source><year>2017</year><volume>11</volume><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">28553417</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="webpage"><collab>World Health Organization</collab><source>Antibiotic Resistance</source><year>2018</year><date-in-citation>Last accessed on 2020 Jan 03</date-in-citation><comment>Available from: <uri xlink:type="simple" xlink:href="https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance">https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance</uri></comment></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>HF</given-names></name><name><surname>Deleo</surname><given-names>FR</given-names></name></person-group><article-title>Waves of resistance: <italic>Staphylococcus aureus</italic> in the antibiotic era</article-title><source>Nat Rev Microbiol</source><year>2009</year><volume>7</volume><fpage>629</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">19680247</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akinyele</surname><given-names>T</given-names></name><name><surname>Igbinosa</surname><given-names>E</given-names></name><name><surname>Akinpelu</surname><given-names>D</given-names></name><name><surname>Okoh</surname><given-names>A</given-names></name></person-group><article-title><italic>In vitro</italic> assessment of the synergism between extracts of <italic>Cocos nucifera</italic> husk and some standard antibiotics</article-title><source>Asian Pac J Trop Biomed</source><year>2017</year><volume>7</volume><fpage>306</fpage><lpage>13</lpage></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uzair</surname><given-names>B</given-names></name><name><surname>Hameed</surname><given-names>A</given-names></name><name><surname>Nazir</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>BA</given-names></name><name><surname>Fasim</surname><given-names>F</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Synergism between <italic>Nigella sativa</italic> seeds extract and synthetic antibiotics against Mec A gene positive human strains of <italic>Staphylococcus aureus</italic></article-title><source>Int J Pharmacol</source><year>2017</year><volume>13</volume><fpage>958</fpage><lpage>68</lpage></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navr&#x000e1;tilov&#x000e1;</surname><given-names>A</given-names></name><name><surname>Ne&#x00161;uta</surname><given-names>O</given-names></name><name><surname>Van&#x0010d;atov&#x000e1;</surname><given-names>I</given-names></name><name><surname>&#x0010c;&#x000ed;&#x0017e;ek</surname><given-names>A</given-names></name><name><surname>Varela-M</surname><given-names>RE</given-names></name><name><surname>L&#x000f3;pez-Ab&#x000e1;n</surname><given-names>J</given-names></name><etal/></person-group><article-title>C-Geranylated flavonoids from <italic>Paulownia tomentosa</italic> fruits with antimicrobial potential and synergistic activity with antibiotics</article-title><source>Pharm Biol</source><year>2016</year><volume>54</volume><fpage>1398</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">26789098</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzotam</surname><given-names>JK</given-names></name><name><surname>Simo</surname><given-names>IK</given-names></name><name><surname>Bitchagno</surname><given-names>G</given-names></name><name><surname>Celik</surname><given-names>I</given-names></name><name><surname>Sandjo</surname><given-names>LP</given-names></name><name><surname>Tane</surname><given-names>P</given-names></name><etal/></person-group><article-title><italic>In vitro</italic> antibacterial and antibiotic modifying activity of crude extract, fractions and 3',4',7-trihydroxyflavone from <italic>Myristica fragrans</italic> Houtt against MDR Gram-negative enteric bacteria</article-title><source>BMC Complement Altern Med</source><year>2018</year><volume>18</volume><fpage>15</fpage><pub-id pub-id-type="pmid">29334931</pub-id></element-citation></ref></ref-list></back></article>